PEAK PROCESSING LIMITED — Regulatory Filings 2019

Nov 13, 2019

==> picture [595 x 148] intentionally omitted <==

ASX Announcement | 14 November 2019 Althea Group Holdings (ASX:AGH)

Althea’s MyAccess Clinics secures licence with UK health regulator

INVESTMENT HIGHLIGHTS:

• Althea’s MyAccess Clinics’ Bristol site has received a licence from the Care Quality Commission (CQC), the independent regulator of health and social care in England

• CQC registration allows for domiciliary care, meaning MyAccess Clinics prescribers are now available for home care services

• MyAccess Clinics is only the second medical cannabis clinic in the UK to receive a CQC licence

• Launched in mid-2019, MyAccess Clinics is Althea’s chain of private medical clinics in the UK

14 November 2019: Australian medicinal cannabis company Althea Group Holdings Limited (ASX:AGH) (‘Althea’ or ‘the Company’) is pleased to announce that the Bristol site of its wholly owned subsidiary, MMJ Clinic Group Limited t/a MyAccess Clinics, has been registered with and received a licence from the Care Quality Commission (CQC), the independent regulator of health and social care in England.

MyAccess Clinics’ Bristol site has become only the second medical cannabis clinic in the UK, and the first located outside of London, to be granted a CQC licence. Approval of the CQC licence is a significant milestone for MyAccess Clinics and for the medical cannabis market in the UK as it provides further regulatory acceptance of cannabis-based medicines being utilised as a treatment option for chronic health conditions.

CQC registration also allows for domiciliary care, meaning MyAccess Clinics prescribers are now available for home care services. The CQC registration can extend to further clinics as part of the company’s expansion plans.

MyAccess Clinics currently has approximately 100 patients on its waiting list and the credibility associated with its newly granted CQC licence will assist in the recruitment of further prescribers.

MyAccess Clinics also expects to soon receive patients from Project TWENTY21, the UK’s first national pilot for medical cannabis, which aims to enrol 20,000 patients before the end of 2021 [ASX Announcement: 25 June 2019].

MyAccess Clinics Clinical Director Graham Woodward said: “We’re delighted to have received our CQC registration and licence, which I am confident will be a turning point for patients who have so far been unable to access medical cannabis in the UK. The CQC licence will allow our physicians to prescribe with absolute confidence, along with now being able to assess patients in their own homes. I also trust this development will bring renewed hope for the reported 1.4 million people in the UK using ‘street cannabis’ to treat their chronic health conditions, now that they will have increased access to expert care and high-quality medical cannabis products.”

Althea CEO Josh Fegan said: “Althea is very proud of Graham and the team at MyAccess Clinics. As a leading medical educator and product supplier in Australia and the UK we have a great understanding of the medical cannabis clinic model. This led us to invest in MyAcccess Clinics and gives us confidence that patients in the UK will receive a gold standard of care from MyAccess Clinics prescribers. The granting of the CQC licence signifies a market leading position for MyAccess Clinics and Althea looks forward to supporting its growth.”

==> picture [595 x 92] intentionally omitted <==

-ENDS-

==> picture [595 x 148] intentionally omitted <==

For further information, please contact:

Althea Media Enquiries Josh Fegan Julia Maguire CEO & Managing Director The Capital Network M: 1300 70 20 20 M: +61 419 815 386 E: contact@althea.life E: julia@thecapitalnetwork.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH). Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into emerging markets throughout Asia and Europe.

To learn more, please visit: www.althea.life

MyAccess Clinics

MyAccess Clinics is a chain of medical clinics in the United Kingdom.

MyAccess Clinics provides expert care for patients with unmet needs, that licensed medicines have failed to address, through the use of ‘specials’ medicines including unlicensed cannabis-based products for medical use.

To learn more, please visit: www.myaccessclinics.co.uk

==> picture [595 x 92] intentionally omitted <==